Evidence map›Paper›PMID 33173425›Full record

ArticleInternational journal of medical sciences2020

Naringenin exerts anticancer effects by inducing tumor cell death and inhibiting angiogenesis in malignant melanoma.

Jawun Choi, Dae-Hyo Lee, Hyuk Jang, Sang-Youel Park, Jae-Won Seol

Open access · goldAbstract read
In one paragraph

Article in International journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 112 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Nephroprotective Effect of Methanolic Extract ofInternational journal of molecular sciences · 2026
    Article
  7. Review
  8. Review
  9. The Therapeutic Potential ofMolecules (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Characterization of Ultrasound-ExtractedFoods (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Review
  19. Review
  20. An Updated Review Summarizing the Anticancer Potential of Naringenin.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jawun ChoiCollege of Veterinary Medicine, Jeonbuk National University, Iksan, Jeollabuk-do 54596, Republic of Korea.
Dae-Hyo LeeCollege of Veterinary Medicine, Jeonbuk National University, Iksan, Jeollabuk-do 54596, Republic of Korea.
Hyuk JangCollege of Veterinary Medicine, Jeonbuk National University, Iksan, Jeollabuk-do 54596, Republic of Korea.
Sang-Youel ParkCollege of Veterinary Medicine, Jeonbuk National University, Iksan, Jeollabuk-do 54596, Republic of Korea.
Jae-Won SeolCollege of Veterinary Medicine, Jeonbuk National University, Iksan, Jeollabuk-do 54596, Republic of Korea.
Jeonbuk National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant melanoma is one of the most deadly skin cancer, due to its aggressive proliferation and metastasis. Naringenin, abundantly present in citrus fruits, has widely studied in cancer therapy. In this study, we investigated whether naringenin also has anticancer effects against B16F10 murine and SK-MEL-28 human melanoma cells. Moreover, we assessed the effects of naringenin treatment on angiogenesis of HUVECs and

Indexed as

Angiogenesis InhibitorsAnimalsApoptosisCell Line, TumorFlavanonesHumansMelanoma, ExperimentalMiceNeovascularization, PathologicRatsSkin NeoplasmsAngiogenesis InhibitorsFlavanonesnaringeninAngiogenesisApoptosisFlavonoidsHUVECsMelanomaNaringenin

Identifiers

PMID33173425
PMCPMC7646117
OpenAlexW3096474543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.